Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma

被引:1
|
作者
Cao, Yenong [1 ]
Afzal, Muhammad Zubair [2 ]
Shirai, Keisuke [2 ]
机构
[1] Dartmouth Hitchcock Med Ctr, Dept Internal Med, Lebanon, NH 03766 USA
[2] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
关键词
skin cancer; unwanted effects; adverse reactions;
D O I
10.1136/bcr-2021-243713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mucosal melanoma is a rare subtype of melanoma and represents a unique diagnosis and treatment challenge. Immune-checkpoint inhibitors (ICIs) have revolutionised metastatic melanoma treatment, and one of the leading regimens is the combination of ipilimumab (anti-cytotoxic T lymphocyte-associated antigen 4: CTLA4) and nivolumab (anti-programmed cell death protein 1: PD1). We report a case of a patient with metastatic mucosal melanoma treated with ipilimumab and nivolumab who developed multiple immune-related adverse events (irAEs) including uveitis, type I diabetes complicated by diabetic ketoacidosis, destructive thyroiditis, hepatitis and vitiligo. Endocrinopathies including type 1 diabetes and hypothyroidism were treated with insulin and levothyroxine. Hepatitis was responsive to steroids. She had sustained complete response 12 months after discontinuation of the combination therapy. With the wide usage of ICIs in multiple types of malignancies, it is important for general practioners to recognise common and serious irAEs due to ICIs.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Correlation between immune-related adverse events and outcomes in nivolumab/ipilimumab combination therapy for metastatic melanoma
    Rauwerdink, Daan
    Frederick, Dennie T.
    Sharova, Tatyana
    Marie, Genevieve
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [2] Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma
    Mehta, Anurag
    Gupta, Arjun
    Hannallah, Franck
    Koshy, Thomas
    Reimold, Sharon
    MELANOMA RESEARCH, 2016, 26 (03) : 319 - 320
  • [4] Efficacy and immune-related adverse events of ipilimumab and nivolumab combination therapy for a vaginal malignant melanoma
    Mitsutake, Yano
    Kota, Konishi
    Mamiko, Okamoto
    Kaei, Nasu
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2022, 153
  • [5] Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
    Freeman-Keller, Morganna
    Kim, Youngchul
    Cronin, Heather
    Richards, Allison
    Gibney, Geoffrey
    Weber, Jeffrey S.
    CLINICAL CANCER RESEARCH, 2016, 22 (04) : 886 - 894
  • [6] Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Ikeda, Takashi
    Ishihara, Hiroki
    Nemoto, Yuki
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Takagi, Toshio
    Iizuka, Junpei
    Hashimoto, Yasunobu
    Ishida, Hideki
    Kondo, Tsunenori
    Tanabe, Kazunari
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) : 735.e9 - 735.e16
  • [7] Experience of immune-related adverse events associated with ipilimumab and nivolumab in a single center.
    Rapoport, Bernardo Leon
    Smit, Teresa
    van Eeden, Ronwyn
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [9] Immune related adverse events associated with ipilimumab and nivolumab
    Rapoport, B.
    Van Eeden, R. I.
    Smit, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
    Moura, Bianca Gautron
    Gerard, Camille L.
    Testart, Nathalie
    Caikovski, Marian
    Wicky, Alexandre
    Aedo-Lopez, Veronica
    Berthod, Gregoire
    Homicsko, Krisztian
    Prior, John O.
    Dromain, Clarisse
    Kandalaft, Lana E.
    Cuendet, Michel A.
    Michielin, Olivier
    CANCERS, 2023, 15 (01)